Overview

Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies

Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
It is well known that blindness is one of the most feared disabilities expressed by patients in the United States. Estimates of the economic impact of visual disability in the current population exceed 30 million US dollars in this country alone. The reasons for this figure are many; however age related macular degeneration (ARMD), diabetic retinopathy, glaucoma and uveitis are responsible for the majority of permanent visual disability and hence the costs in both quality of life and placing an economic burden on society. Research that may help reverse various abnormal biological responses that lead to or worsen clinical manifestations of diabetic retinopathy would be valuable.
Phase:
N/A
Details
Lead Sponsor:
Wake Forest School of Medicine
Wake Forest University
Treatments:
Methotrexate